This trial is testing a new drug to treat a certain type of lung cancer that has come back.
- Non-Small Cell Lung Cancer
1 Primary · 3 Secondary · Reporting Duration: Up to approximately 3 years
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
60 Total Participants · 1 Treatment Group
Primary Treatment: Cofetuzumab Pelidotin · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Cofetuzumab Pelidotin been sanctioned by the FDA?
"There is limited clinical data in regards to the safety and efficacy of Cofetuzumab Pelidotin, thus it has been assigned a score of 1." - Anonymous Online Contributor
How widely available is this research endeavor?
"Patients are being enrolled at Stanford Univ School Medicine /ID# 213450 (Stanford, CA), Virginia Cancer Specialists /ID# 216427 (Fairfax, VA) and Sylvester Comprehensive Cancer /ID# 216433 (Miami, FL). Additionally there are 18 other sites participating." - Anonymous Online Contributor
Is enrollment for the experiment still available at this time?
"Affirmative. Clinicaltrials.gov data reveals that this research initiative, which was initially uploaded to the website on February 13th 2020, is presently admitting participants. Sixty individuals must be recruited from 18 distinct healthcare centres." - Anonymous Online Contributor
How many persons are being included in this investigation?
"Affirmative. Clinicaltrials.gov holds evidence that this clinical trial is still ongoing, having been initially posted on February 13th 2020 and updated most recently on November 24th 2022. A total of 60 patients are being sought after by 18 different medical sites across the country." - Anonymous Online Contributor